Evidence & regulatory context
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
- Target
- CHEMBL224; CHEMBL225; CHEMBL217
- Injury models
- TBI · Spinal cord injury
- Reported indication
- Not recorded
- First approval
- 1997
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Atrolak xl; Biquelle xl; Brancico xl; Ebesque xl; Mintreleq xl; Norsic; NSC-758918; Psyquet xl; Quetiapina; Quetiapine; Quetiapine extended release; Seotiapim xl; Seroquel; Seroquel xl; Sondate xl
- Note
- Not recorded
Clinical trials 7
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR
Schizophrenia
Enrolment: 120 · Results not recorded
Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States (ARMS)
Abnormal Mental State · Schizophrenia
Enrolment: 83 · Results not recorded
Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression
Depression
Enrolment: 126 · Results not recorded
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL) as Monotherapy in the Treatment of Patients With MDD
Major Depressive Disorder
Enrolment: 600 · Results not recorded
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL) as Monotherapy in the Treatment of Patients With MDD
Major Depressive Disorder
Enrolment: 600 · Results not recorded
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia: a Randomized Clinical Trial
Psychiatric Disorders · Insomnia
Enrolment: 255 · Results not recorded
Quetiapine as a Prophylactic Agent for Early Postoperative Delirium in High Risk Patients in Open Heart Surgeries
Delirium
Enrolment: 60 · Results not recorded
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MixedTBIControlled cortical impactC57BL/6Malen = 5 animals per groupIntravenous in vivo; culture medium in vitro10 mg/kg in vivo; 20 micromolar for cell studies10 minutes after traumatic brain injury in vivo; 1 h pretreatment before chitos…
Model: Mild to moderate controlled cortical impact traumatic brain injury, with sham craniotomy controls; in vitro chitosan-activated endothelial hyperpermeability
Quetiapine significantly reduced blood-brain barrier hyperpermeability and matrix metalloproteinase-9 activity after traumatic brain injury and preserved tight and adherens junction integrity in vitro.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
RatSpinal cord injuryCompressionWistarFemalen = 32Intraperitoneal10 mg/kg/day
Model: Clip compression spinal cord injury
Quetiapine reduced apoptotic cell counts at both the 1 day and 7 day timepoints
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
